Dapagliflozin for kidney disease to improve heart structure
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 study tests whether dapagliflozin can improve heart structure and function in people with chronic kidney disease (CKD). Dapagliflozin is a kidney-heart medicine that may affect how the heart changes over time, measured by heart scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (age 18 or older) and sign informed consent
- Have CKD based on kidney blood test results (eGFR in the allowed range) and/or high urine protein levels
- Be on stable blood-pressure kidney-protecting medicine (ACE inhibitor or ARB) at a steady dose for at least 4 weeks
- If you have type 2 diabetes, your diabetes medicines must be stable for over 30 days before screening
- If you can become pregnant, use approved birth control methods during the study and for 30 days after; or be postmenopausal/surgically sterile
- Understand and read Danish (study team language requirement)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking dapagliflozin (a drug often used for diabetes and heart health) can help improve kidney structure and blood flow in people who received a kidney transplant at least 9 months ago. It may benefit those whose kidney function is stable, regardless of whether they have diabetes.
This trial tests if empagliflozin, a medicine that helps control blood sugar and protect the kidneys, is safe and effective for people with type 2 diabetes who have very low kidney function (eGFR between 10 and 20). It aims to see if the drug can still benefit the heart and kidneys at this stage.
This study tests if matching treatments to your specific kidney disease markers can better protect your kidneys. It looks at how well Finerenone, Dapagliflozin, and Semaglutide work alone or in a sequence.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This trial tests if dapagliflozin helps reduce fat around the heart in people with a type of heart failure where the heart pumps normally but is stiff. It might improve symptoms and overall health.
Hear when a new Chronic Kidney Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.